Welcome to our dedicated page for Procter & Gamble SEC filings (Ticker: PG), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Procter & Gamble Company filings document material-event reporting for an Ohio-incorporated consumer products issuer with PG common stock listed on the New York Stock Exchange. The company’s recent 8-K records identify its registered common stock and a broad schedule of exchange-listed notes.
Those disclosures cover capital-structure reference points, including U.S. dollar, euro and British pound notes with maturities spanning short- and long-dated issues. The filings also provide recurring public-company identifiers, exchange listings and formal reporting details tied to P&G’s securities.
The Procter & Gamble Company security holder has filed a notice of intent to sell 95,903 shares of common stock. The shares are expected to be sold on or about 01/23/2026 on the NYSE through Morgan Stanley Smith Barney LLC, with an indicated aggregate market value of $14,018,141.51.
The planned sale is tied to the exercise and sale of stock options, with the options acquired and paid in cash on 01/23/2026. The filing notes that Procter & Gamble had 2,336,733,549 shares outstanding, which is a baseline figure, not the amount being sold.
The Procter & Gamble Company filed a current report to share that it issued a press release announcing its second quarter results and held a related conference call. The company is also making available a set of informational slides that were referenced on the call and posted on its website.
This report is furnished under Regulation FD, which is meant to ensure all investors have access to the same information at the same time. The filing also lists the company’s common stock and various outstanding debt securities that are registered for trading on the New York Stock Exchange.
The Procter & Gamble Company filed a current report to furnish its latest quarterly earnings release. The company issued a news release covering results for the quarter ended December 31, 2025, and is providing this report under the “Results of Operations and Financial Condition” item.
The filing identifies Procter & Gamble’s common stock and multiple series of notes listed on the NYSE and attaches the earnings news release as an exhibit. This report serves mainly as a formal SEC submission of the previously issued earnings information.
The Procter & Gamble Company disclosed that its Board of Directors declared a quarterly dividend of $1.0568 per share on its Common Stock and on its Series A and Series B ESOP Convertible Class A Preferred Stock. The dividend is payable on or after February 17, 2026 to Common Stock shareholders of record at the close of business on January 23, 2026, and to the ESOP preferred shareholders of record at the start of business on the same date. This filing simply reports the Board’s latest dividend decision under Regulation FD.
The Procter & Gamble Company disclosed that Jennifer Davis, currently Chief Executive Officer - Health Care, has notified the company of her intent to retire. The notice was given on December 9, 2025, and her retirement is expected to be effective June 30, 2026.
Davis is retiring after more than 33 years of service with Procter & Gamble, reflecting a long tenure in senior leadership. The filing does not provide additional details on succession or changes to the company’s broader strategy.
Procter & Gamble (PG) director Robert Portman reported a small equity compensation grant. On 12/09/2025, he acquired 54 shares of Procter & Gamble common stock through restricted stock units at a price of $0, reflecting a stock-based award rather than an open-market purchase.
The award was granted under The Procter & Gamble 2025 Stock and Incentive Compensation Plan and includes dividend equivalents in the form of additional restricted stock units. Following this transaction, Portman beneficially owns 4,983.9036 shares of Procter & Gamble common stock in direct ownership.
Procter & Gamble director reports stock award under compensation plan. A company director received an award of 215 shares of Procter & Gamble common stock on 12/09/2025, recorded at a price of $0 per share. The award was granted under The Procter & Gamble 2025 Stock and Incentive Compensation Plan.
Following this grant, the director directly beneficially owns 5,562.7456 shares of common stock. This total includes dividend equivalents that were granted in the form of restricted stock units, so it reflects both shares and related stock-based incentives.
Procter & Gamble reported an insider equity award for director Christine M. McCarthy on Form 4. On 12/09/2025, she received 269 shares of Procter & Gamble common stock in the form of Restricted Stock Units, shown at a price of $0 per unit because they are part of her compensation rather than an open-market purchase. These units were granted under The Procter & Gamble 2025 Stock and Incentive Compensation Plan, and her total beneficial ownership after this award is 16,808.9761 shares.
The total ownership figure also includes dividend equivalents that are credited as additional Restricted Stock Units, which means her position can gradually grow as dividends are paid. This filing reflects routine equity compensation for a board member, rather than a large discretionary buy or sale in the market.
Procter & Gamble (PG) reported an insider equity grant to one of its directors. On 12/09/2025, a director acquired 260 shares of common stock in the form of restricted stock units with a stated price of $0, reflecting an award rather than an open-market purchase. The award was made under The Procter & Gamble 2025 Stock and Incentive Compensation Plan, and the director’s total beneficial ownership after this transaction is 10,978.2065 shares, including dividend equivalents granted as additional restricted stock units.
Procter & Gamble director Joseph Jimenez reported an equity award from the company. On 12/09/2025, he acquired 341 shares of common stock, shown at a price of $0, reflecting a grant of Restricted Stock Units under The Procter & Gamble 2025 Stock and Incentive Compensation Plan. Following this award, he is shown as beneficially owning 36,083.677 shares of Procter & Gamble common stock in direct ownership. The total includes dividend equivalents granted in the form of additional Restricted Stock Units.